HIV/AIDS continues to be a menace to public health. Several drugs currently on the market have successfully improved the ability to manage the viral burden in infected patients. However, new drugs are needed to combat the rapid emergence of mutated forms of the virus that are resistant to existing therapies. Currently, approved drugs target three of the four major enzyme activities encoded by the virus that are critical to the HIV life cycle. Although a number of inhibitors of HIV RNase H activity have been reported, few inhibit by directly engaging the RNase H active site. Here, we describe structures of naphthyridinone-containing inhibitors bound to the RNase H active site. This class of compounds binds to the active site via two metal ions that are coordinated by catalytic site residues, D443, E478, D498, and D549. The directionality of the naphthyridinone pharmacophore is restricted by the ordering of D549 and H539 in the RNase H domain. In addition, one of the naphthyridinone-based compounds was found to bind at a second site close to the polymerase active site and non-nucleoside/nucleotide inhibitor sites in a metal-independent manner. Further characterization, using fluorescence-based thermal denaturation and a crystal structure of the isolated RNase H domain reveals that this compound can also bind the RNase H site and retains the metal-dependent binding mode of this class of molecules. These structures provide a means for structurally guided design of novel RNase H inhibitors.
BackgroundThe unique S28 family of proteases is comprised of the carboxypeptidase PRCP and the aminopeptidase DPP7. The structural basis of the different substrate specificities of the two enzymes is not understood nor has the structure of the S28 fold been described.ResultsThe experimentally phased 2.8 Å crystal structure is presented for human PRCP. PRCP contains an α/β hydrolase domain harboring the catalytic Asp-His-Ser triad and a novel helical structural domain that caps the active site. Structural comparisons with prolylendopeptidase and DPP4 identify the S1 proline binding site of PRCP. A structure-based alignment with the previously undescribed structure of DPP7 illuminates the mechanism of orthogonal substrate specificity of PRCP and DPP7. PRCP has an extended active-site cleft that can accommodate proline substrates with multiple N-terminal residues. In contrast, the substrate binding groove of DPP7 is occluded by a short amino-acid insertion unique to DPP7 that creates a truncated active site selective for dipeptidyl proteolysis of N-terminal substrates.ConclusionThe results define the structure of the S28 family of proteases, provide the structural basis of PRCP and DPP7 substrate specificity and enable the rational design of selective PRCP modulators.
Highlights d Unprecedented allosteric small-molecule binder to PCSK9 was identified using AS/MS d Biased and unbiased hit-to-lead strategy identified binders through divergent SAR d Demonstrated binding of lead compound to PCSK9 in a cellular thermal shift assay d Developed lead compound into targeted degrader achieving 60% reduction of PCSK9 levels
The search for new molecular constructs that resemble the critical two-metal binding pharmacophore required for HIV integrase strand transfer inhibition represents a vibrant area of research within drug discovery. Here we present the discovery of a new class of HIV integrase strand transfer inhibitors based on the 2-pyridinone core of MK-0536. These efforts led to the identification of two lead compounds with excellent antiviral activity and preclinical pharmacokinetic profiles to support a once-daily human dose prediction. Dose escalating PK studies in dog revealed significant issues with limited oral absorption and required an innovative prodrug strategy to enhance the high-dose plasma exposures of the parent molecules.
Indoleamine-2,3-dioxygenase-1
(IDO1) has emerged as a target of
significant interest to the field of cancer immunotherapy, as the
upregulation of IDO1 in certain cancers has been linked to host immune
evasion and poor prognosis for patients. In particular, IDO1 inhibition
is of interest as a combination therapy with immune checkpoint inhibition.
Through an Automated Ligand Identification System (ALIS) screen, a
diamide class of compounds was identified as a promising lead for
the inhibition of IDO1. While hit 1 possessed attractive
cell-based potency, it suffered from a significant right-shift in
a whole blood assay, poor solubility, and poor pharmacokinetic properties.
Through a physicochemical property-based approach, including a focus
on lowering AlogP98 via the strategic introduction of polar
substitution, compound 13 was identified bearing a pyridyl
oxetane core. Compound 13 demonstrated improved whole
blood potency and solubility, and an improved pharmacokinetic profile
resulting in a low predicted human dose.
Indoleamine-2,3-dioxygenase-1 (IDO1)
has emerged as an attractive
target for cancer immunotherapy. An automated ligand identification
system screen afforded the tetrahydroquinoline class of novel IDO1
inhibitors. Potency and pharmacokinetic (PK) were key issues with
this class of compounds. Structure-based drug design and strategic
incorporation of polarity enabled the rapid improvement on potency,
solubility, and oxidative metabolic stability. Metabolite identification
studies revealed that amide hydrolysis in the D-pocket was the key
clearance mechanism for this class. Strategic survey of amide isosteres
revealed that carbamates and N-pyrimidines, which
maintained exquisite potencies, mitigated the amide hydrolysis issue
and led to an improved rat PK profile. The lead compound 28 is a potent IDO1 inhibitor, with clean off-target profiles and the
potential for quaque die dosing in humans.
Allosteric integrase inhibitors (ALLINIs) bind to the lens epithelial-derived growth factor (LEDGF) pocket on HIV-1 integrase (IN) and possess potent antiviral effects. Rather than blocking proviral integration, ALLINIs trigger IN conformational changes that have catastrophic effects on viral maturation, rendering the virions assembled in the presence of ALLINIs noninfectious. A high-throughput screen for compounds that disrupt the IN·LEDGF interaction was executed, and extensive triage led to the identification of a t-butylsulfonamide series, as exemplified by 1. The chemical, biochemical, and virological characterization of this series revealed that 1 and its analogs produce an ALLINI-like phenotype through engagement of IN sites distinct from the LEDGF pocket. Key to demonstrating target engagement and differentiating this new series from the existing ALLINIs was the development of a fluorescence polarization probe of IN (FLIPPIN) based on the t-butylsulfonamide series. These findings further solidify the late antiviral mechanism of ALLINIs and point toward opportunities to develop structurally and mechanistically novel antiretroviral agents with unique resistance patterns.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.